Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma
Phase 2
18+
7 sites in AZ, CA, GA +3
What this study is about
This Phase 2 study is testing Gemcitabine 1000 mg in people with adenocarcinoma. The primary outcome being measured is Progression-Free Survival (PFS).
Simplified from trial records by PatientMatch.
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Assignment is predetermined by the study protocol.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
gemcitabine, paclitaxel (Taxane chemotherapy; stabilizes microtubules)
injection (Injection), infusion
Primary: Progression-Free Survival (PFS)
Secondary: AUC of Nab-paclitaxel, Area Under the Plasma Concentration-time Curve (AUC) of Relacorilant, Best Overall Response (BOR), Clinical Benefit Rate (CBR), Cmax of Nab-paclitaxel, Duration of Response (DoR), Maximum Plasma Concentration (Cmax) of Relacorilant, Number of Patients with 1 or More Adverse Events
Oncology